Skip to Content

'
Robert L. Coleman, M.D., FACOG, FACS

Present Title & Affiliation

Primary Appointment

Professor, Department of Gynecologic Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX
Director of Clinical Research, Department of Gynecologic Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX

Bio Statement

Dr. Coleman was recruited back to the M.D. Anderson faculty in 2004 to help expand and coordinate the Department of Gynecologic Oncology clinical therapeutics program. Finishing the institution’s Gynecologic Oncology fellowship in 1993, he has distinguished himself as a key opinion leader in cancers of the female genital tract. He has authored and co-authored numerous peer-reviewed scientific publications, book chapters, monographs, invited articles and textbooks including, The Handbook of Gynecologic Oncology, Clinical Lymphatic Mapping in Gynecologic Cancers and Prognostic and Predictive Factors in Gynecological Cancers. He is a frequently invited lecturer for national and international conferences and meetings where he continues to foster international scientific collaboration.

Before returning to M.D. Anderson, Dr. Coleman served as Division Director of Gynecologic Oncology at Creighton University School of Medicine and Vice-Chairman of Obstetrics and Gynecology at The University of Texas Southwestern Medical Center in Dallas. There he held the inaugural Patricia Duniven-Fletcher Professorship of Gynecologic Oncology. Dr. Coleman’s research interests include novel therapeutics for ovarian, uterine and cervical cancer, clinical trial development and statistical design, surgical innovations and graduate education. He is the institution’s Gynecologic Oncology Group (GOG) Principal Investigator (PI) and is PI or Co-PI for several GOG prospective clinical trials including a national, multicenter, randomized trial evaluating chemotherapy and surgery for recurrent ovarian cancer, several trials of novel chemotherapeutics and biologics in cancers of the ovary, cervix and uterus and two trials evaluating lymphatic mapping for gynecologic malignancies. He currently is a co-Project leader for the MDACC Ovarian SPORE, The Ovarian Cancer Research Fund, and the Marcus Foundation, each of which is sponsoring novel therapeutics trials in gynecologic cancers.

Dr. Coleman currently serves on the Editorial Board of several peer-reviewed scientific publications. He is an active member of many national organizations including the Society of Gynecologic Oncologists, the American College of Surgeons and the American Society of Clinical Oncology. Dr. Coleman serves as the chairman of the Department of Gynecologic Oncology Research Administration Committee, is a member of the Blanton-Davis Ovarian Cancer Research Program Executive Committee and is a Member of the Board for the Gynecologic Cancer Foundation.

Office Address

The University of Texas M. D. Anderson Cancer Center
1155 Herman Pressler Drive
Unit Number: 1362
Houston, TX 77030
Room Number: CPB6.3244
Fax: (713) 792-7586

Education & Training

Degree-Granting Education

1987 Creighton University School of Medicine, Omaha, NE, MD, Medicine
1983 Creighton University, Omaha, NE, BS, Mathematics

Postgraduate Training

7/1991-7/1993 Fellowship, Gynecologic Oncology, University of Texas M. D. Anderson Cancer Center, Houston, TX, J. Taylor Wharton, M.D.
7/1987-7/1991 Residency, Obstetrics and Gynecology, Northwestern University Medical Center, Chicago, IL, Jack Sciarra, M.D.

Board Certifications

1/1996 American Board of Obstetrics and Gynecology, Division of Gynecologic Oncology
1/1994 American Board of Obstetrics and Gynecology
1/1987 National Board of Medical Examiners

Experience/Service

Academic Appointments

Associate Professor, Department of Gynecologic Oncology, University of Texas M. D. Anderson Cancer Center, Houston, TX, 7/2004-8/2006
Associate Professor, Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center, Dallas, TX, 9/2000-7/2004
Assistant Professor, Obstetrics & Gynecology, University of Texas Southwestern Medical Center, Dallas, TX, 9/1996-8/2000
Assistant Professor, Obstetrics and Gynecology, Creighton University School of Medicine, Omaha, NE, 7/1993-8/1996

Other Appointments/Responsibilities

Member, Board of Directors, Gynecologic Cancer Foundation, Chicago, IL, 3/2006-present
Director, Department of Obstetrics & Gynecology, Creighton University School of Medicine, Omaha, NE, 7/1993-6/1996

Endowed Positions

Patricia Duniven Fletcher Professor in Gynecologic Oncology, Obstetrics and Gynecology, University of Texas Southwestern Medical Center, Dallas, TX, 2/2001-7/2004

Institutional Committee Activities

Member, M. D. Anderson Conflict of Interest Committee, 9/2006-present

Professional Memberships

American Association for Cancer Research (AACR)
Member, 2000-present
American Association of Cancer Researchers
Member, 1999-present
American Board of Obstetrics and Gynecology (ABOG)
Member, Division of Gynecologic Oncology, 2008-present
Examiner, Division of Gynecologic Oncology, 2006-present
Examiner, 2001-present
American College of Obstetricians and Gynecologists (ACOG)
Fellow, 1994-present
American College of Surgeons (ACS),
Fellow, 1997-present
American Gynecological & Obstetrical Society (AGOS), Washington, DC
Fellow, 2007-present
American Society of Clinical Oncology (ASCO)
Member, Grants Selection Committee, 2006-present
Member, 1997-present
Association of Professors of Gynecology and Obstetrics (APGO)
Member, 1994-present
Felix Rutledge Society
Program Chairman, 2003
Member, 1993-present
Gynecologic Oncology Group (GOG)
Member, Developmental Therapeutics Committee, 12/2005-present
Institutional Principal Investigator, 8/2005-present
Institutional Co-Principal Investigator, 7/2004-8/2005
Member, Ovarian Committee, 11/2000-present
Institutional Co-Principal Investigator, 1/1990-7/2004
Gynecological Cancer Foundation
Member, Board of Directors, 2006-present
Faculty, Ovarian Cancer Survivors Courses, 2005-present
Member, Membership Committee, 1997-present
International Gynecologic Cancer Society (IGCS)
Member, IGCS 12th Annual Scientific Program Committee, 2008
Member, 2002-present
Society of Gynecologic Oncologists (SGO)
Member, Membership Committee, 1998-present
Western Association of Gynecologic Oncologists (WAGO)
Member, 1998-present

Selected Publications

Peer-Reviewed Original Research Articles
1. Lee JW, Han HD, Shahzad MM, Kim SW, Mangala LS, Nick AM, Lu C, Langley RR, Schmandt R, Kim HS, Mao S, Gooya J, Fazenbaker C, Jackson D, Tice DA, Landen CN, Coleman RL, Sood AK. EphA2 Immunoconjugate as Molecularly Targeted Chemotherapy for Ovarian Carcinoma. J Natl Cancer Inst 101(17):1193-205, 9/2/2009. e-Pub 7/29/2009. PMCID: PMC2736292.
2. Tao X, Sood AK, Deavers MT, Schmeler KM, Nick AM, Coleman RL, Milojevic L, Gershenson DM, Brown J. Anti-angiogenesis therapy with bevacizumab for patients with ovarian granulosa cell tumors. Gynecol Oncol 114(3):431-6, 9/2009. e-Pub 6/13/2009. PMID: 19524286.
3. Merritt WM, Danes CG, Shahzad M, Lin YG, Kamat AA, Han LY, Spannuth WA, Nick AM, Mangala LS, Stone RL, Kim HS, Gershenson DM, Jaffe RB, Coleman RL, Chandra J, Sood AK. Anti-angiogenic properties of metronomic topotecan in ovarian carcinoma. Cancer Biol Ther 8(16), 8/13/2009. e-Pub 8/13/2009. PMID: 19738426.
4. Levenback CF, van der Zee AG, Rob L, Plante M, Covens A, Schneider A, Coleman R, Solima E, Hertel H, Barranger E, Obermair A, Roy M. Sentinel lymph node biopsy in patients with gynecologic cancers Expert panel statement from the International Sentinel Node Society Meeting, February 21, 2008. Gynecol Oncol 114(2):151-6, 8/2009. PMID: 19457548.
5. Shahzad MK, Lu C, Lee JW, Stone RL, Mitra R, Mangala LS, Lu Y, Baggerly KA, Danes CG, Nick AM, Halder JB, Kim HS, Vivas-Mejia P, Landen CN, Lopez-Berestein G, Coleman RL, Sood AK. Dual Targeting of EphA2 and FAK in Ovarian Carcinoma. Cancer Biol Ther 8(11). e-Pub 6/24/2009. PMID: 19395869.
6. Mangala LS, Zuzel V, Schmandt R, Leshane ES, Halder JB, Armaiz-Pena GN, Spannuth WA, Tanaka T, Shahzad M, Lin YG, Nick AM, Danes CG, Lee JW, Jennings NB, Vivas-Mejia PE, Wolf JK, Coleman RL, Siddik ZH, Lopez-Berestein G, Lutsenko S, Sood AK. Therapeutic targeting of ATP7B in ovarian carcinoma. Clin Cancer Res 15(11):3770-80, 6/1/2009. e-Pub 5/26/2009. PMID: 19470734.
7. Moroney JW, Sood AK, Coleman RL. Aflibercept in epithelial ovarian carcinoma. Future Oncol 5(5):591-600, 6/2009. PMID: 19519199.
8. Sood AK, Coleman RL, et al. EphA2 overexpression is associated with lack of hormone receptor expression and poor outcome in endometrial cancer. Cancer 115(12):2684-92, 4/24/2009. e-Pub 4/24/2009. PMID: 19396818.
9. Gershenson DM, Sun CC, Bodurka DC, Coleman RL, Lu KH, Sood AK, Deavers M, Malpica AL, Kavanagh JJ,. Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant. Gynecol Oncol 114(1). e-Pub 4/9/2009. PMID: 19361839.
10. Spannuth WA, Nick AM, Jennings NB, Armaiz-Pena GN, Mangala LS, Danes CG, Lin YG, Merritt WM, Thaker PH, Kamat AA, Han LY, Tonra JR, Coleman RL, Ellis LM, Sood AK. Functional significance of VEGFR-2 on ovarian cancer cells. Int J Cancer 124(5):1045-1053, 3/1/2009. e-Pub 9/2008. PMCID: PMC2668132.
11. Santoso JT, Azadi A, Wan J, Handorf C, Coleman RL, Tillmanns TD. Lymph node counts in uterine cancer: A randomized double blind trial. Gynecol Oncol 113(2). e-Pub 3/4/2009. PMID: 19268343.
12. Gilcrease M, Coleman RL, et al. Primary peritoneal serous carcinoma presenting as inflammatory breast cancer. Breast J 15(2):176-81, Mar-Apr, 3/2009. PMID: 19292804.
13. Kamat AA, Coleman RL. Erythropoeisis-stimulating agents (ESAs) in cervix cancer: The "black box" paradox. Cancer Biol Ther 8(1). e-Pub 1/29/2009. PMID: 19127119.
14. Merritt WM, Lin YG, Han LY, Kamat AA, Spannuth WA, Schmandt R, Urbauer D, Pennacchio LA, Cheng JF, Nick AM, Deavers MT, Mourad-Zeidan A, Wang H, Mueller P, Lenburg ME, Gray JW, Mok S, Birrer MJ, Lopez-Berestein G, Coleman RL, Bar-Eli M, Sood AK. Dicer, Drosha, and Outcomes in Patients with Ovarian Cancer. N Engl J Med 359(25):2641-2650, 12/18/2008. PMCID: PMC2710981.
15. Jandial DD, Soliman PT, Slomovitz BM, Schmeler KM, Levenback C, Coleman RL, Ramirez PT. Laparoscopic colostomy in gynecologic cancer. J Minim Invasive Gynecol 15(6):723-8, Nov-Dec, 11/2008. PMID: 18971136.
16. Coleman RL. Lymphatic mapping for vulvar cancer: ready for "prime-time?". Curr Oncol Rep 10(6):493-6, 11/2008. PMID: 18928663.
17. Herzog TJ, Powell MA, Rader JS, Gibb RK, Lippmann L, Coleman RL, Mutch DG. Phase II evaluation of topotecan and navelbine in patients with recurrent ovarian, fallopian tube or primary peritoneal cancer. Gynecol Oncol 111(3). e-Pub 9/30/2008. PMID: 18834619.
18. Lin YG, Immaneni A, Merritt WM, Mangala LS, Kim SW, Shahzad MM, Tsang YT, Armaiz-Pena GN, Lu C, Kamat AA, Han LY, Spannuth WA, Nick AM, Landen CN, Wong KK, Gray MJ, Coleman RL, Bodurka DC, Brinkley WR, Sood AK. Targeting aurora kinase with MK-0457 inhibits ovarian cancer growth. Clin Cancer Res 14(17):5437-46, 9/1/2008. PMID: 18765535.
19. Coleman RL, Kohn EC. Rationale for combination use of targeted agents in ovarian cancer: do we have one? Cancer 113(4):665-7, 8/15/2008. PMID: 18623195.
20. Coleman RL, Levine DA. 44th Annual Meeting of the American Society of Clinical Oncology. Gynecol Oncol 110(2):123-4, 8/2008. PMID: 18649408.
21. Hwang JY, Mangala LS, Fok JY, Lin YG, Merritt WM, Spannuth WA, Nick AM, Fiterman DJ, Vivas-Mejia PE, Deavers MT, Coleman RL, Lopez-Berestein G, Mehta K, Sood AK. Clinical and biological significance of tissue transglutaminase in ovarian carcinoma. Cancer Res 68(14):5849-58, 7/2008. PMCID: PMC2547344.
22. Coleman RL, Coleman RL. The Gynecologic Oncology Group's role in the treatment of recurrent cervix cancer: Current clinical trials. Gynecol Oncol 110(3S2):S77-S80, 6/25/2008. e-Pub 6/26/2008. PMID: 18584855.
23. Ramirez PT, Schmeler KM, Milam MR, Slomovitz BM, Smith JA, Kavanagh JJ, Deavers M, Levenback C, Coleman RL, Gershenson DM. Efficacy of letrozole in the treatment of recurrent platinum- and taxane-resistant high-grade cancer of the ovary or peritoneum. Gynecol Oncol 110(1). e-Pub 5/5/2008. PMID: 18457865.
24. Ramirez PT, Frumovitz M, Dos Reis R, Milam MR, Bevers MW, Levenback CF, Coleman RL. Modified uterine manipulator and vaginal rings for total laparoscopic radical hysterectomy. Int J Gynecol Cancer 18(3):571-5, 5/2008. e-Pub 8/2007. PMID: 17692091.
25. Spannuth WA, Sood AK, Coleman RL. Angiogenesis as a strategic target for ovarian cancer therapy. Nat Clin Pract Oncol 5(4):194-204, 4/2008. e-Pub 2/2008. PMID: 18268546.
26. Lu C, Thaker PH, Lin YG, Spannuth W, Landen CN, Merritt WM, Jennings NB, Langley RR, Gershenson DM, Yancopoulos GD, Ellis LM, Jaffe RB, Coleman RL, Sood AK. Impact of vessel maturation on anti-angiogenic therapy in ovarian cancer. Am J Obstet Gynecol 198(4):477.e1-9, 4/2008. PMCID: PMC2346589.
27. Isonishi S, Coleman RL, Hirama M, Iida Y, Kitai S, Nagase M, Ochiai K. Analysis of Prognostic Factors for Patients with Leiomyoma treated with Uterine Arterial Embolization. Am J Obstet Gynecol 198(3):270.e1-6, 3/2008. e-Pub 11/2007. PMID: 17997392.
28. Frumovitz M, Gayed IW, Jhingran A, Euscher ED, Coleman RL, Ramirez PT, Levenback CF. Lymphatic mapping and sentinel lymph node detection in women with vaginal cancer. Gynecol Oncol 108(3):478-81, 3/2008. e-Pub 1/2008. PMID: 18190952.
29. Schmeler KM, Sun CC, Bodurka DC, Deavers MT, Malpica A, Coleman RL, Ramirez PT, Gershenson DM. Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum. Gynecol Oncol 108(3):510-4, 3/2008. e-Pub 12/2007. PMID: 18155273.
30. Ramirez PT, Landen CN, Coleman RL, Milam MR, Levenback C, Johnston TA, Gershenson DM. Phase I Trial of the Proteasome Inhibitor Bortezomib in Combination with Carboplatin in Patients with Platinum- and Taxane-Resistant Ovarian Cancer. Gynecol Oncol 108(1):68-71, 1/2008. e-Pub 10/2007. PMID: 17905421.
31. Gatcliffe TA, Coleman RL. Tumor board: more than treatment planning--a 1-year prospective survey. J Cancer Educ 23(4):235-7, 2008. PMID: 19058072.
32. dos Reis R, Frumovitz M, Milam MR, Capp E, Sun CC, Coleman RL, Ramirez PT. Adenosquamous Carcinoma versus Adenocarcinoma in Early-Stage Cervical Cancer Patients Undergoing Radical Hysterectomy: An Outcomes Analysis. Gynecol Oncol 107(3):458-63, 12/2007. e-Pub 9/2007. PMID: 17854872.
33. Kamat AA, Merritt WM, Coffey D, Lin YG, Patel PR, Broaddus R, Nugent E, Han LY, Landen CN, Spannuth WA, Lu C, Coleman RL, Gershenson DM, Sood AK. Clinical and biological significance of vascular endothelial growth factor in endometrial cancer. Clin Cancer Res 13(24):7487-95, 12/2007. PMID: 18094433.
34. Coleman RL. Gemcitabine plus carboplatin compared with carboplatin alone for platinum-sensitive recurrent ovarian cancer. Curr Oncol Rep 9(6):469-71, 11/2007. PMID: 17991354.
35. Kim TJ, Ravoori M, Landen CN, Kamat AA, Han LY, Lu C, Lin YG, Merritt WM, Jennings N, Spannuth WA, Langley R, Gershenson DM, Coleman RL, Kundra V, Sood AK. Antitumor and antivascular effects of AVE8062 in ovarian carcinoma. Cancer Res 67(19):9337-45, 10/2007. PMID: 17909042.
36. Li Y, Finkel KW, Hu W, Fu S, Liu J, Coleman RL, Kavanagh JJ. Pegylated liposomal doxorubicin treatment in recurrent gynecologic cancer patients with renal dysfunction. Gynecol Oncol 106(2):375-80, 8/2007. e-Pub 5/2007. PMID: 17512575.
37. Lu C, Kamat AA, Lin YG, Merritt WM, Landen CN, Kim TJ, Spannuth W, Arumugam T, Han LY, Jennings NB, Logsdon C, Jaffe RB, Coleman RL, Sood AK. Dual targeting of endothelial cells and pericytes in antivascular therapy for ovarian carcinoma. Clin Cancer Res 13(14):4209-17, 7/2007. PMID: 17634550.
38. Crotzer DR, Sun CC, Coleman RL, Wolf JK, Levenback CF, Gershenson DM. Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary. Gynecol Oncol 105(2):404-8, 5/2007. e-Pub 2/9/2007. PMID: 17292461.
39. Saucier JM, Yu J, Gaikwad A, Coleman RL, Wolf JK, Smith JA. Determination of the optimal combination chemotherapy regimen for treatment of platinum-resistant ovarian cancer in nude mouse model. J Oncol Pharm Pract 13(1):39-45, 3/2007. PMID: 17621566.
40. Milam MR, Sood AK, King S, Bassett RL, Lu KH, Slomovitz BM, Coleman RL, Ramirez PT. Supracervical hysterectomy in patients with advanced epithelial ovarian cancer. Obstet Gynecol 109(3):641-6, 3/2007. PMID: 17329515.
41. Coleman RL. 7th annual International Conference on Ovarian Cancer. Expert Rev Anticancer Ther 7(2):119-21, 2/2007. PMID: 17288523.
42. Lu C, Bonome T, Li Y, Kamat AA, Han LY, Schmandt R, Coleman RL, Gershenson DM, Jaffe RB, Birrer MJ, Sood AK. Gene alterations identified by expression profiling in tumor-associated endothelial cells from invasive ovarian carcinoma. Cancer Res 67(4):1757-68, 2/2007. PMID: 17308118.
43. Kamat AA, Kim TJ, Landen CN, Lu C, Han LY, Lin YG, Merritt WM, Thaker PH, Gershenson DM, Bischoff FZ, Heymach JV, Jaffe RB, Coleman RL, Sood AK. Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer. Cancer Res 67(1):281-8, 1/1/2007. PMID: 17210709.
44. Coleman RL, Gordon A, Barter J, Sun S, Rackoff W, Herzog TJ. Early changes in CA125 after treatment with pegylated liposomal doxorubicin or topotecan do not always reflect best response in recurrent ovarian cancer patients. Oncologist 12(1):72-8, 1/2007. PMID: 17227902.
45. Landen CN, Merritt WM, Mangala LS, Sanguino AM, Bucana C, Lu C, Lin YG, Han LY, Kamat AA, Schmandt R, Coleman RL, Gershenson DM, Lopez-Berestein G, Sood AK. Intraperitoneal Delivery of Liposomal siRNA for Therapy of Advanced Ovarian Cancer. Cancer Biol Ther 5:1708-13, 12/2006. PMID: 17106249.
46. Naumann RW, Coleman RL. The use of adjuvant radiation therapy in early endometrial cancer by members of the Society of Gynecologic Oncologists in 2005. Gynecol Oncol 105(1):7-12, 12/2006. e-Pub 12/20/2006. PMID: 17187847.
47. Coleman RL, Sood AK. Historical progress in the initial management of ovarian cancer: intraperitoneal chemotherapy. Curr Oncol Rep 8:455-64, 11/2006. PMID: 17040624.
48. Coleman RL. Intraperitoneal chemotherapy for frontline ovarian cancer therapy: vindicated or vilified? Curr Oncol Rep 8:439-440, 11/2006. PMID: 17091543.
49. Gossner G, Coleman RL, Mutch DG, Horowitz NS, Rader JS, Gibb RK, Powell MA, Herzog TJ.. CA-125 response in patients with recurrent ovarian or primary peritoneal cancer treated with pegylated liposomal doxorubicin or topotecan. Gynecol Oncol 103:212-8, 10/2006. PMID: 16677696.
50. Han LY, Landen CN, Trevino JG, Halder J, Lin YG, Kamat AA, Kim TJ, Merritt WM, Coleman RL, Gershenson DM, Shakespeare WC, Wang Y, Sundaramoorth R, Metcalf CA, 3rd, Dalgarno DC, Sawyer TK, Gallick GE, Sood AK. Antiangiogenic and antitumor effects of SRC inhibition in ovarian carcinoma. Cancer Res 66(17):8633-9, 9/2006. PMID: 16951177.
51. Slomovitz BM, Ramirez PT, Frumovitz M, Soliman PT, Bevers M, Coleman RL, Levenback C. Electrothermal bipolar coagulation for pelvic exenterations. Gynecol Oncol 102(3):534-6, 9/2006. PMID: 16483643.
52. Frumovitz M, Bodurka DC, Broaddus RR, Coleman RL, Sood AK, Gershenson DM, Burke TW, Levenback CF. Lymphatic mapping and sentinel node biopsy in women with high-risk endometrial cancer. Gynecol Oncol 104(1):100-3, 9/2006. e-Pub 9/11/2006. PMID: 16963111.
53. Herzog TJ, Coleman RL, Guerrieri JP, Jr, Gabriel K, Du W, Techner L, Fort JG, Wallin B. A double-blind, randomized, placebo-controlled phase III study of the safety of alvimopan in patients who undergo simple total abdominal hysterectomy. Am J Obstet Gynecol 195(2):445-53, 8/2006. PMID: 16626607.
54. Thaker PH, Han LY, Kamat AA, Arevalo JM, Takahashi R, Lu C, Jennings NB, Armaiz-Pena G, Bankson JA, Ravoori M, Merritt WM, Lin YG, Mangala LS, Kim TJ, Coleman RL, Landen CN, Li Y, Felix E, Sanguino AM, Newman RA, Lloyd M, Gershenson DM, Kundra V, Lopez-Berestein G, Lutgendorf SK, Cole SW, Sood AK. Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med 12(8):939-44, 8/2006. PMID: 16862152.
55. Gershenson DM, Sun CC, Lu KH, Coleman RL, Sood AK, Malpica A, Deavers MT, Silva EG, Bodurka DC. Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary. Obstet Gynecol 108(2):361-8, 8/2006. PMID: 16880307.
56. Halder J, Kamat AA, Landen CN, Jr, Han LY, Lutgendorf SK, Lin YG, Merritt WM, Jennings NB, Chavez-Reyes A, Coleman RL, Gershenson DM, Schmandt R, Cole SW, Lopez-Berestein G, Sood AK. Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy. Clin Cancer Res 12(16):4916-24, 8/2006. PMID: 16914580.
57. Herzog TJ, Coleman RL, Markman M, Cella D, Thigpen JT. The role of maintenance therapy and novel taxanes in ovarian cancer. Gynecol Oncol 102(2):218-25, 8/2006. PMID: 16460787.
58. Ramirez PT, Slomovitz BM, Soliman PT, Coleman RL, Levenback C. Total laparoscopic radical hysterectomy and lymphadenectomy: the M. D. Anderson Cancer Center experience. Gynecol Oncol 102(2):252-5, 8/2006. PMID: 16472844.
59. Ramirez PT, Slomovitz BM, McQuinn L, Levenback C, Coleman RL. Role of appendectomy at the time of primary surgery in patients with early-stage ovarian cancer. Gynecol Oncol 103:888-90, 6/2006. PMID: 16806436.
60. Rao GG, Kurien A, Gossett D, Griffith WF, Coleman RL, Muller CY. A case-control study of methylenetetrahydrofolate reductase polymorphisms in cervical carcinogenesis. Gynecol Oncol 101(2):250-4, 5/2006. PMID: 16297972.
61. Coleman RL, Frumovitz M, Levenback CF. Current perspectives on lymphatic mapping in carcinomas of the uterine corpus and cervix. J Natl Compr Canc Netw 4(5):471-8, 5/2006. PMID: 16687095.
62. Coleman RL, Broaddus RR, Bodurka DC, Wolf JK, Burke TW, Kavanagh JJ, Levenback CF, Gershenson DM. Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers. Gynecol Oncol 101(1):126-31, 4/2006. PMID: 16271384.
63. Frumovitz M, Coleman RL, Gayed IW, Ramirez PT, Wolf JK, Gershenson DM, Levenback CF. Usefulness of preoperative lymphoscintigraphy in patients who undergo radical hysterectomy and pelvic lymphadenectomy for cervical cancer. Am J Obstet Gynecol 194(4):1186-93; discussion 1193-5, 4/2006. PMID: 16580331.
64. Coleman NM, Smith-Zagone MJ, Tanyi J, Anderson ML, Coleman RL, Dyson SW, Reed JA. Primary neuroendocrine carcinoma of the vagina with Merkel cell carcinoma phenotype. Am J Surg Pathol 30(3):405-10, 3/2006. PMID: 16538063.
65. Gallion H, Christopherson WA, Coleman RL, DeMars L, Herzog T, Hosford S, Schellhas H, Wells A, Sevin BU. Progression-free interval in ovarian cancer and predictive value of an ex vivo chemoresponse assay. Int J Gynecol Cancer 16:194-201, 1/2006. PMID: 16445633.
66. Sood AK, Coleman RL, Wolf JK, Gershenson DM. Selected highlights from the 5th International Conference on Ovarian Cancer. Houston, TX, USA, 1-4 December 2004. Expert Opin Pharmacother 6(7):1269-75, 6/2005. PMID: 15957979.
67. Fujiwara K, Markman M, Morgan M, Coleman RL. Intraperitoneal carboplatin-based chemotherapy for epithelial ovarian cancer. Gynecol Oncol 97(1):10-5, 4/2005. PMID: 15790431.
68. Rao GG, Rogers P, Drake RD, Nguyen P, Coleman RL. Phase I clinical trial of weekly paclitaxel, weekly carboplatin, and concurrent radiotherapy for primary cervical cancer. Gynecol Oncol 96(1):168-72, 2005. PMID: 15589596.
69. Bhoola SM, Coleman RL, Herzog T, Morris R, Bryant C, Estes JM, Alvarez RD. Retrospective analysis of weekly topotecan as salvage therapy in relapsed ovarian cancer. Gynecol Oncol 95(3):564-9, 12/2004. PMID: 15581964.
70. Moschos E, Coleman RL. Acquiring laparoscopic skill proficiency: does orientation matter? Am J Obstet Gynecol 191(5):1782-7, 11/2004. PMID: 15547564.
71. Munkarah AR, Coleman RL. Critical evaluation of secondary cytoreduction in recurrent ovarian cancer. Gynecol Oncol 95(2):273-80, 11/2004. PMID: 15491746.
72. Drake RD, Lin WM, King M, Farrar D, Miller DS, Coleman RL. Oral dexamethasone attenuates Doxil-induced palmar-plantar erythrodysesthesias in patients with recurrent gynecologic malignancies. Gynecol Oncol 94(2):320-4, 8/2004. PMID: 15297168.
73. Rao GG, Skinner E, Gehrig PA, Duska LR, Coleman RL, Schorge JO. Surgical staging of ovarian low malignant potential tumors. Obstet Gynecol 104(2):261-6, 8/2004. PMID: 15291997.
74. Delin JB, Miller DS, Coleman RL. Other primary malignancies in patients with uterine corpus malignancy. Am J Obstet Gynecol 190(5):1429-31, 5/2004. PMID: 15167859.
75. Lea JS, Coleman R, Kurien A, Schorge JO, Miller DS, Minna JD, Muller CY. Aberrant p16 methylation is a biomarker for tobacco exposure in cervical squamous cell carcinogenesis. Am J Obstet Gynecol 190(3):674-9, 3/2004. PMID: 15041998.
76. Schorge JO, Lea JS, Elias KJ, Rajanbabu R, Coleman RL, Miller DS, Ashfaq R. P16 as a molecular biomarker of cervical adenocarcinoma. Am J Obstet Gynecol 190(3):668-73, 3/2004. PMID: 15041997.
77. Santoso JT, Cannada T, O'Farrel B, Alladi K, Coleman RL. Subjective versus objective nutritional assessment study in women with gynecological cancer: a prospective cohort trial. Int J Gynecol Cancer 14(2):220-3, 3/2004. PMID: 15086719.
78. Santoso JT, Schwertner B, Coleman RL, Hannigan EV. Tumor board in gynecologic oncology. Int J Gynecol Cancer 14(2):206-9, 3/2004. PMID: 15086716.
79. Lea JS, Coleman RL, Garner EO, Duska LR, Miller DS, Schorge JO. Adenosquamous histology predicts poor outcome in low-risk stage IB1 cervical adenocarcinoma. Gynecol Oncol 91(3):558-62, 12/2003. PMID: 14675676.
80. Schorge JO, Lea JS, Farrar DF, King MR, Coleman RL, Miller DS. Management of low-risk gestational trophoblastic neoplasia in indigent women. J Reprod Med 48(10):780-4, 10/2003. PMID: 14628732.
81. Corton MM, Wai CY, Vakili B, Boreham MK, Schaffer JI, Coleman RL. A comprehensive pelvic dissection course improves obstetrics and gynecology resident proficiency in surgical anatomy. Am J Obstet Gynecol 189(3):647-51, 9/2003. PMID: 14526284.
82. Santoso JT, Lucci JA, 3rd, Coleman RL, Schafer I, Hannigan EV. Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: a randomized trial. Cancer Chemother Pharmacol 52(1):13-8, 7/2003. PMID: 12719883.
83. Schorge JO, Lea JS, Garner EO, Duska LR, Miller DS, Coleman RL. Cervical adenocarcinoma survival among Hispanic and white women: a multicenter cohort study. Am J Obstet Gynecol 188(3):640-4, 3/2003. PMID: 12634634.
84. Vlahou A, Schorge JO, Gregory BW, Coleman RL. Diagnosis of Ovarian Cancer Using Decision Tree Classification of Mass Spectral Data. J Biomed Biotechnol 2003(5):308-314, 2003. PMID: 14688417.
85. Coleman RL. Vulvar lymphatic mapping: coming of age? Ann Surg Oncol 9:823-5, 11/2002. PMID: 12417500.
86. Lea JS, Shin CH, Sheets EE, Coleman RL, Gehrig PA, Duska LR, Miller DS, Schorge JO. Endocervical curettage at conization to predict residual cervical adenocarcinoma in situ. Gynecol Oncol 87(1):129-32, 10/2002. PMID: 12468353.
87. Muller CY, Coleman RL, Toler K, Gibbons D, Ashfaq R, Voet RL. Adequacy of oophorectomy at the time of gynecologic surgery. Int J Gynaecol Obstet 77(1):23-9, 4/2002. PMID: 11929652.
88. Coleman RL, Muller CY. Effects of a laboratory-based skills curriculum on laparoscopic proficiency: a randomized trial. Am J Obstet Gynecol 186(4):836-42, 4/2002. PMID: 11967517.
89. Coleman RL, Mahoney NM, Hatch KD. Laparoscopic management of urolithiasis in a continent urostomy. Gynecol Oncol 84(3):473-8, 3/2002. PMID: 11855892.
90. Lea JS, Sheets EE, Duska LR, Miller DS, Schorge JO. Early-stage cervical adenocarcinoma treated by surgical intent: the role of para-aortic lymph node dissection. Gynecol Oncol 84(2):285-8, 2/2002. PMID: 11812088.
91. Levenback C, Coleman RL, Burke TW, Lin WM, Erdman W, Deavers M, Delpassand ES. Lymphatic mapping and sentinel node identification in patients with cervix cancer undergoing radical hysterectomy and pelvic lymphadenectomy. J Clin Oncol 20(3):688-93, 2/2002. PMID: 11821449.
92. Coleman RL. Emerging role of topotecan in front-line treatment of carcinoma of the ovary. Oncologist 7 Suppl 5:46-55, 2002. PMID: 12324633.
93. Lea JS, Sheets EE, Wenham RM, Duska LR, Coleman RL, Miller DS, Schorge JO. Stage IIB-IVB cervical adenocarcinoma: prognostic factors and survival. Gynecol Oncol 84(1):115-9, 2002. PMID: 11748986.
94. Schorge JO, Mahoney NM, Miller DS, Coleman RL, Muller CY, Euhus DM, Tomlinson GE. Germline BRCA1-2 mutations in non-Ashkenazi families with double primary breast and ovarian cancer. Gynecol Oncol 83(2):383-7, 11/2001. PMID: 11606101.
95. Levenback C, Coleman RL, Burke TW, Bodurka-Bevers D, Wolf JK, Gershenson DM. Intraoperative lymphatic mapping and sentinel node identification with blue dye in patients with vulvar cancer. Gynecol Oncol 83(2):276-81, 11/2001. PMID: 11606084.
96. O'Boyle JD, Coleman RL, Bernstein SG, Lifshitz S, Muller CY, Miller DS. Intraoperative lymphatic mapping in cervix cancer patients undergoing radical hysterectomy: A pilot study. Gynecol Oncol 79(2):238-43, 11/2000. PMID: 11063651.
97. Von Gruenigen VE, Coleman RL, Li AJ, Heard MC, Miller DS, Hemsell DL. Bacteriology and treatment of malodorous lower reproductive tract in gynecologic cancer patients. Obstet Gynecol 96(1):23-7, 7/2000. PMID: 10862836.
98. Muller CY, Coleman RL, Adams WP, Jr. Laparoscopy in patients following transverse rectus abdominis myocutaneous flap reconstruction. Obstet Gynecol 96(1):132-5, 7/2000. PMID: 10928902.
99. Santoso JT, Canada T, Latson B, Aaaadi K, Lucci JA, 3rd, Coleman RL. Prognostic nutritional index in relation to hospital stay in women with gynecologic cancer. Obstet Gynecol 95(6 Pt 1):844-6, 6/2000. PMID: 10831978.
100. Coleman RL Santoso JT. Vulvar carcinoma. Curr Treat Options Oncol 1(2):177-90, 6/2000. PMID: 12057056.
101. Lin WM, Michalopulos EA, Dhurander N, Cheng PC, Robinson W, Ashfaq R, Coleman RL, Muller CY. Allelic loss and microsatellite alterations of chromosome 3p14.2 are more frequent in recurrent cervical dysplasias. Clin Cancer Res 6(4):1410-4, 4/2000. PMID: 10778971.
102. Coleman RL, Lindberg G, Muller CY, Miller DS, Hameed A. Ectopic production and localization of beta-human chorionic gonadotropin in lymphoepithelioma-like carcinoma of the cervix: a case report. Int J Gynecol Pathol 19(2):179-82, 4/2000. PMID: 10782417.
103. Hameed A, Coleman RL. . Fine-needle aspiration cytology of primary granulosa cell tumor of the adrenal gland: a case report. Diagn Cytopathol 22:107-9, 2/2000. PMID: 10649522.
104. von Gruenigen VE, Coleman RL, King MR, Miller DS. Abdominal compartment syndrome in gynecologic surgery. Obstet Gynecol 94(5 Pt 2):830-2, 11/1999. PMID: 10546746.
105. Hameed A, Miller DS, Muller CY, Coleman RL, Albores-Saavedra J. Frequent expression of beta-human chorionic gonadotropin (beta-hCG) in squamous cell carcinoma of the cervix. Int J Gynecol Pathol 18(4):381-6, 10/1999. PMID: 10542948.
106. Von Gruenigen VE, O'Boyle JD, Coleman RL, Wilson D, Miller DS, Mathis JM. Efficacy of intraperitoneal adenovirus-mediated p53 gene therapy in ovarian cancer. Int J Gynecol Cancer 9(5):365-372, 9/1999. PMID: 11240795.
107. Coleman RL, Whitten CW, O'Boyle J, Sidhu B. Unexplained decrease in measured oxygen saturation by pulse oximetry following injection of Lymphazurin 1% (isosulfan blue) during a lymphatic mapping procedure. J Surg Oncol 70(2):126-9, 2/1999. PMID: 10084657.
108. Santoso JT, Lucci JA, 3rd, Coleman RL, Hatch S, Wong P, Miller D, Mathis JM. Does glutamine supplementation increase radioresistance in squamous cell carcinoma of the cervix? Gynecol Oncol 71(3):359-63, 12/1998. PMID: 9887231.
109. von Gruenigen VE, Santoso JT, Coleman RL, Muller CY, Miller DS, Mathis JM. In vivo studies of adenovirus-based p53 gene therapy for ovarian cancer. Gynecol Oncol 69(3):197-204, 6/1998. PMID: 9648587.
110. Santoso JT, Coleman RL, Voet RL, Bernstein SG, Lifshitz S, Miller D. Pathology slide review in gynecologic oncology. Obstet Gynecol 91(5 Pt 1):730-4, 5/1998. PMID: 9572220.
111. Coleman RL, Miller DS. Topotecan in the treatment of gynecologic cancer. Semin Oncol 24(6 Suppl 20):S20-55-S20-63, 12/1997. PMID: 9425962.
112. Coleman RL, Bagnell KG, Townley PM. Carboplatin and short-infusion paclitaxel in high-risk and advanced-stage ovarian carcinoma. Cancer J Sci Am 3(4):246-53, 7/1997. PMID: 9263631.
113. Burke TW, Levenback C, Coleman RL, Morris M, Silva EG, Gershenson DM. Surgical therapy of T1 and T2 vulvar carcinoma: further experience with radical wide excision and selective inguinal lymphadenectomy. Gynecol Oncol 57(2):215-20, 5/1995. PMID: 7729737.
114. Coleman RL, Keeney ED, Freedman RS, Burke TW, Eifel PJ, Rutledge FN. Radical hysterectomy for recurrent carcinoma of the uterine cervix after radiotherapy. Gynecol Oncol 55(1):29-35, 10/1994. PMID: 7959262.
115. Lynch HT, Lynch J, Conway T, Watson P, Coleman RL. Familial aggregation of carcinoma of the endometrium. Am J Obstet Gynecol 171(1):24-7, 7/1994. PMID: 8030707.
116. Coleman RL, Burke TW, Morris M, Eifel PJ, Hallum AV, 3rd, Wallace S, Tornos C. Intraoperative radiographs to confirm the adequacy of lymph node resection in patients with suspicious lymphangiograms. Gynecol Oncol 51(3):362-7, 12/1993. PMID: 8112646.
117. Coleman RL, Schink JC, Miller DS, Bauer KD, August CZ, Rademaker AW, Lurain JR. DNA flow cytometric analysis of clinical stage I endometrial carcinomas with lymph node metastases. Gynecol Oncol 50:20-4, 7/1993. PMID: 8349159.

Book Chapters
1. Alpa M. Nick, Robert L. Coleman, and Anil K. Sood. Molecular therapeutics in epithelial ovarian cancer. In: Ovarian Cancer: State of the Art, 1. Ed(s) Robert C. Bast, Jr. and Maurie Markman. Remedica: London, UK, 109-160, 2009. PMID: 978-1-905721-53-5.
2. Ramirez PT, Levenback C, Coleman RL. Laparoscopic Sentinel Lymph Node Identification in Cervical Cancer. In: Nezhat's Operative Gynecologic Laparoscopy and Hysteroscopy, Third. Ed(s) Camran Nezhat, Farr Nezhat, Ceana Nezhat. Cambridge University Press: New York, 447-452, 2008.
3. Han LY, Coleman RL. Ovarian Cancer Staging. In: Gynecologic Procedures for the General Surgeon, Operative Techniques in General Surgery. 9, Issue 2. Ed(s) Koltun WA. Elsevier: Philadelphia, 51-91, 2007.
4. Rao GG Coleman RL. Fallopian tube cancer. In: Gynecology & Obstetrics. JB Lippincott, 2004.
5. Herzog TJ, Kost ER, Coleman RL. Gynecology. In: Laparoscopic Surgery: Principles and Procedures. Marcel Dekker, Inc, 2004.
6. Coleman RL Coleman FK. Radiotherapy in vulvar carcinoma. In: Gynecology & Obstetrics. JB Lippincott, 2004.
7. Coleman RL, Munkarah A, Bristow RE. Secondary cytoreductive surgery. In print. In: Surgery for Ovarian Cancer: Principles and Practice. Parthenon Publishing Group Limited, 2004.
8. Coleman RL. Lymphatic mapping. In: An Atlas of Gynecologic Oncology. Taylor & Francis Books, Ltd, 2003.
9. Coleman RL. Secondary cytoreduction surgery for ovarian cancer. In Production. In: Principles and Practice. Parthenon Publishing, 2003.
10. Coleman RL. Anatomy and natural history of invasive female lower genital tract cancers (FLGTCs): Carcinomas of the cervix, vagina, and vulva. In: Atlas of Clinical Oncology. B.C. Decker Inc, 47-62, 2001.
11. Coleman RL Santoso JT. Vulvar carcinoma. In: Current Treatment Options in Oncology. 1(2). Current Science, Inc, 177-190, 2000.
12. Coleman RL Coleman FK. Radiotherapy in epithelial ovarian cancer. In: Gynecology & Obstetrics. 4:37. Williams & Wilkins/JB Lippincott, 1-15, 1999.
13. Coleman RL. Fallopian tube carcinoma. In: Gynecology & Obstetrics. 4:36. JB Lippincott, 1-90, 1998.
14. Hallum AV, Coleman RL, Wolf J. Gynecologic oncology. In: The M. D. Anderson Surgical Oncology Handbook. Little, Brown and Co, 326-368, 1995.
15. Coleman RL. The retroperitoneal mass. In: Management of Complications in Gynecologic Surgery. WB Saunders Company, 115-126, 1995.

Books (edited and written)
1. Lee P. Shulman, M.D. Ed(s) Lee P. Schulman, M.D. 2007 Year Book of Obstetrics, Gynecology, and Women's Health. In: 2007 Year Book Series. Elsevier: Philadelphia, PA, 2007.
2. Levenback, C, Coleman RL, Lu K, Sood AK. Ed(s) Levenback, C, Coleman RL, Lu K, Sood AK. Prognostic and Predictive Factors in Gynecologic Cancers, 1. Informa UK Ltd. London, 2007. PMID: 0415391725.
3. Levenback C, Coleman R, Van der Zee AGJ. Clinical Lymphatic Mapping in Gynecologic Cancers. Martin Dunitz Ltd, 2004.
4. Santoso JT Coleman RL. Handbook of Gyn Oncology. McGraw-Hill, 2001.
5. Gershenson DM (ed) Coleman RL (guest ed). Operative Techniques in Gynecologic Surgery. WB Saunders Company, 2001.
6. Hallum AV, Coleman RL, Segreti E. Epithelial ovarian cancer. In: Study Guide for Textbook of Gynecology. WB Saunders Company, 1994.

Manuals, Teaching Aids, Other Teaching Publications
1. Coleman RL. Living Medical Textbook from Projects in Knowledge CME Activity - Oncology Women's Cancers Edition, Chapter 4 Recurrent Ovarian Cancer: State of the State. Projects in Knowledge: Little Falls, NJ, 01/19/2009 - 01/19/2010. e-Pub 1/2009.
2. Ovarian Cancer Update: Conversations with Oncology Investigators, Bridging the Gap between Research and Patient Care. 1, Issue 2. Ed(s) Neil Love, M.D. Research To Practice: Miami, FL, 6/2008.
3. Coleman RL, Herzog TJ. Ovarian and Cervical Cancer: Emerging Therapeutic Paradigms. Continuing Edge: USA, 22, 8/2007.

Last updated: 9/23/2009